- Home
- MRK vs AZN Comparison
MRK vs AZN Comparison
Compare MRK & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | AZN |
|---|---|---|
| Founded | 2000 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2B | 316.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRK | AZN |
|---|---|---|
| Price | $120.76 | $183.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $125.59 | N/A |
| AVG Volume (30 Days) | ★ 8.6M | 1.9M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.06% | 1.73% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.61 | $10.34 |
| Revenue Next Year | $5.41 | $6.43 |
| P/E Ratio | ★ N/A | $31.91 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $76.66 | $68.62 |
| 52 Week High | $125.14 | $212.71 |
Technical Indicators
Market Signals| Indicator | MRK | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 52.86 |
| Support Level | $112.96 | $180.98 |
| Resistance Level | $123.93 | $191.50 |
| Average True Range (ATR) | 2.97 | 2.98 |
| MACD | 0.01 | 0.42 |
| Stochastic Oscillator | 77.21 | 80.83 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.